Clinical Trials | December 18, 2025
Astellas & Pfizer report breakthrough Phase 3 results in muscle-invasive bladder cancer
The combination also outperformed chemotherapy on another important secondary endpoint
The combination also outperformed chemotherapy on another important secondary endpoint
Convenient subcutaneous option has potential to reach more patients with same clinical benefits as Saphnelo IV infusion
Hansoh Pharma will receive an upfront payment in the low double-digit millions
The EIR was issued following an inspection of the facility from September 8 to September 16, 2025
The state-of-the-art facility is a 350-bedded, multi-specialty tertiary care hospital
The study also showed a clear dose-dependent trend, with the 75 mg QD group outperforming the 50 mg QD cohort
Indoco received the Establishment Inspection Report from the USFDA for its API manufacturing facility
The positive CHMP opinion is supported by results from the Phase III QUASAR trial
WINREVAIR is currently the first and only activin signalling inhibitor approved for PAH across all 27 EU member states
Glenmark's Leucovorin Calcium for Injection USP, 350 mg/vial Single-Dose Vial is bioequivalent and therapeutically equivalent to the reference listed drug
Subscribe To Our Newsletter & Stay Updated
